Rebecca Benner

Gemtuzumab ozogamicin for <i>de novo</i> acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial

Juliette Lambert, Cécile Pautas, Christine Terré et al. · Haematologica · 2018 · 336 citations · Full text

Azithromycin for the Secondary Prevention of Coronary Heart Disease Events

Christopher M. O’Connor, Michael W. Dunne, Marc A. Pfeffer et al. · JAMA · 2003 · 325 citations

Randomized, Phase III Trial of First-Line Figitumumab in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Advanced Non–Small-Cell Lung Cancer

Corey J. Langer, Silvia Novello, Keunchil Park et al. · Journal of Clinical Oncology · 2014 · 177 citations · Full text

Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

Vera Hirsh, Luis Paz‐Ares, Michael Boyer et al. · Journal of Clinical Oncology · 2011 · 137 citations · Full text

A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer

C. Manegold, Nico van Zandwijk, A. Szczęsna et al. · Annals of Oncology · 2011 · 126 citations · Full text

Oncology, Tlr9 Agonist, Medicine +8